Journals / Medicine Science / 2014 / Cilt: 3 - Sayı: 4

Losartan and QT Dispersion in Hypertensive Patients on Maintenance Hemodialysis

Pages
1627–1638
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Losartan reduced BP and electrocardiographic LVH was improved in HD patients without affecting QTd and QTcd during the 16-week study period.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:QT and corrected QT (QTc) intervals and their increased dispersions (QTd, QTcd) have been linked to the occurrence of arrhythmias in hemodialysis (HD) patients.
📊
Key Findings & Data:Our cohort comprised 24 dialysis patients and 14 healthy controls. 15 dialysis patients were treated for 16 weeks with losartan (HD losartan group) but not 9 patients (HD control group).
💡
Conclusion & Impact:Losartan reduced BP and electrocardiographic LVH was improved in HD patients without affecting QTd and QTcd during the 16-week study period.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

QT and corrected QT (QTc) intervals and their increased dispersions (QTd, QTcd) have been linked to the occurrence of arrhythmias in hemodialysis (HD) patients. This study was performed to determine the effects of the angiotensin II receptor blocker losartan on these parameters in HD patients. Our cohort comprised 24 dialysis patients and 14 healthy controls. 15 dialysis patients were treated for 16 weeks with losartan (HD losartan group) but not 9 patients (HD control group). Blood pressures (BP) and electrocardiogram-derived data (Sokolow-Lyon and Cornell voltages, QT, QTd, QTc and QTcd) were measured in all patients. At the beginning of the study, there were no differences in patient characteristics among the 3 groups. Baseline maximum QTc, QTd, QTcd and Socolow-Lyon and Cornell voltages and BPs of the healthy group were lower than those of HD groups. While these parameters were similar in the dialysis groups, only BPs in losartan group were higher. After 16 weeks, BPs, Socolow-Lyon and Cornell voltages values in losartan group significantly decreased but not in the HD control group. Whereas maximum QT and QTc, QTd, QTcd, heart rate and QRS interval did not change in the HD groups. Electrocardiographic LVH of 2 patients improved in the losartan group. Losartan reduced BP and electrocardiographic LVH was improved in HD patients without affecting QTd and QTcd during the 16-week study period.

🔖

Cite This Article

ERSOY, A., ERSOY, C., EREK, M. G., YILDIZ, A. (2014). Losartan and QT Dispersion in Hypertensive Patients on Maintenance Hemodialysis. Medicine Science, Cilt: 3 - Sayı: 4, 1627–1638. https://ajindex.com/articles/277830

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Guerin AP, Pannier B, Marchais SJ, London GM. Cardiovascular disease in the dialysis population: prognostic significance of arterial disorders. Curr Opin Nephrol Hypertens. 2006;15(2):105-10
  2. Locatelli F, Covic A, Chazot C, Leunissen K, Luno J, Yaqoob M. Hypertension and cardiovascular risk assessment in dialysis patients. Nephrol Dial Transplant. 2004;19(5):1058-68
  3. Zazgornik J, Biesenbach G, Forstenlehner M, Stummvoll K. Profile of antihypertensive drugs in hypertensive pa tients on renal replacement therapy (RRT). Clin Nephrol. 1997;48(6):337-40
  4. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45(4 Suppl 3):S1-153
  5. Toto R1, Shultz P, Raij L, Mitchell H, Shaw W, Ramjit D, Toh J, Shahinfar S. Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group. Hypertension. 1998;31(2):684-91
  6. Saracho R, Martin-Malo A, Martinez I, Aljama P, Montenegro J. Evaluation of the Losartan in Hemodialysis (ELHE) Study. Kidney Int Suppl. 1998;68:S125-129
  7. Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, Inoue T, Araki R. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis. 2008;52(3):501-6
  8. Karnik JA, Young BS, Lew NL, Herget M, Dubinsky C, Lazarus JM, Chertow GM. Cardiac arrest and sudden death in dialysis units. Kidney Int. 2001;60(1):350-7
  9. Himmelfarb J, Ikizler TA. Hemodialysis. N Engl J Med. 2010;363(19):1833-45
  10. Wang CL, Lee WL, Wu MJ, Cheng CH, Chen CH, Shu KH. Increased QTc dispersion and mortality in uremic patients with acute myocardial infarction. Am J Kidney Dis. 2002;39(3):539-48
  11. Saadeh A, Evans S, James M, Jones J. QTc dispersion and complex ventricular arrhythmias in untreated newly presenting hypertensive patients. J Hum Hypertens. 1999;13(10):665-9
  12. Oktavia D, Nasution SA, Setiati S. The clinical factors' prediction of increased intradialytic QT dispersion on the electrocardiograms of chronic hemodialysis patients. Saudi J Kidney Dis Transpl. 2013;24(2):274-80
  13. Lorincz I, Matyus J, Zilahi Z, Kun C, Karanyi Z, Kakuk G. QT dispersion in patients with end-stage renal failure and during hemodialysis. J Am Soc Nephrol. 1999;10(6):1297-302
  14. Morris ST, Galiatsou E, Stewart GA, Rodger RS, Jardine AG. QT dispersion before and after hemodialysis. J Am Soc Nephrol. 1999;10(1):160-163
  15. Brooksby P